Date: 2011-06-15
Type of information: Distribution agreement
Compound: defibrotide
Company: Gentium (Italy) Link Pharmaceuticals (Australia)
Therapeutic area: Digestive diseases - Liver diseases - Transplantation
Type agreement: distribution
Action mechanism:
Disease: treatment and prevention of hepatic veno-occlusive disease (VOD) in haematopoietic stem-cell transplantation therapy, in adults and children
Details: Gentium has announced the appointment of Link Pharmaceuticals as exclusive distributor of defibrotide in Australia and New Zealand. Under the terms of the agreement, Link will be responsible for managing named patient requests.
Financial terms:
Latest news:
